– USA, NY – Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX), a biopharmaceutical company today announced the appointments of Dr. Matt Angel (Ph.D.), Dr. Gregory Fiore (MD), Nicholas Singer and Bill Wexler to its Board of Directors, effective June 5, 2022:
“We are thrilled to welcome Matt Angel, Gregory Fiore, Nicholas Singer, and Bill Wexler to our Board of Directors. Each brings experience in key sectors relevant to our business that will be valuable as we propel the company into its next phase of growth and development,” said Board Chairman, Charles Cherington.
Concurrently, Erich Mohr, Dennis Langer, Heather Redman, and Erin Enright departed the Board effective June 5, 2022.
About Dr. Matt Angel
Dr. Angel is an experienced biotechnology entrepreneur and executive, having led Factor Bioscience Inc. as CEO since its founding in 2011. Dr. Angel is Co-Founder of the immuno-oncology company, Exacis Biotherapeutics, where he serves as Scientific Advisory Board Chair, and the cell therapy company, Novellus Therapeutics, which was acquired by Brooklyn in 2021. Dr. Angel has deep experience in cell therapy product development, intellectual property protection and licensing, contract negotiation, including collaboration and licensing agreements, and has raised more than $150 million through grants, equity financings, and M&A. A pioneer in mRNA technology, Dr. Angel is a prolific inventor with more than 100 patents covering mRNA, nucleic acid delivery, gene editing, and cell reprogramming technologies. Dr. Angel received his Ph.D. from the Massachusetts Institute of Technology, where he studied immunology and synthetic RNA.
About Gregory Fiore
Dr. Fiore is a co-founder and is the President and CEO of Exacis Biotherapeutics. He is a pharmaceutical/biotechnology executive and entrepreneur and is a co-founder and former CEO of Sollis Therapeutics, where during his tenure as CEO he raised ~$50M in funding from State grants as well as strategic venture investors. He oversaw the regulatory strategy development and initiation of pivotal clinical trials for the Company’s lead compound. Before this, he provided C-level medical support as a consultant and acting CM for several early-stage biotechnology companies through two consultancies he founded. Dr. Fiore was the first CMO of The Medicines Company and held a variety of leadership roles at The Medicines Company, Merck, and Abbott Laboratories after spending time as a management consultant at McKinsey and Company. Dr. Fiore completed an Internal Medicine internship and residency as well as received clinical Pulmonary / Critical Care training at Harvard Medical School and received his MD degree from New York Medical College.
About Nicholas Singer
Nicholas J. Singer has over 20 years of experience in finance and investments and is the Founder and Managing Member of Purchase Capital. He is also the Founder and Executive Chairman of United Parks, the Executive Chairman of IntegriCo Composites, the Chairman of Only What You Need, and a Trustee of the Pérez Art Museum Miami. From 2007 to 2013, Mr. Singer was the Co-Founder & Co-Managing Member of Standard General, an SEC-registered investment advisor which managed over $1 billion of assets during his tenure. Before that, he was a Founding Partner of Cyrus Capital Partners, a Principal at Och-Ziff Capital Management, and an Analyst in High Yield Trading and the Principal Investment Area at Goldman Sachs & Co. He graduated summa cum laude with a B.S. in Economics from the Wharton School and a B.A.S. in Electrical Engineering from the School of Engineering and Applied Science at the University of Pennsylvania.
Bill Wexler
Mr. Wexler has worked on over 150 individual projects, serving in various capacities including Chairman; CEO; Chief Restructuring Officer, and other designated roles of senior responsibility. Since 2017, he has served as Chairman of the Board and CEO of Homer City Holdings, LLC which owns and operates a multiple unit merchant power plant which is located in western Pennsylvania. From July 2012 to December 2019, he served in various roles, including as Chairman of the Board, CEO, and sole Director and shareholder representative of Upstate New York Power Products, Inc. which owned and operated merchant power plants throughout upstate New York. From January 2012 to April 2013, Mr. Wexler served as Chief Restructuring Officer of VMR Electronics, LLC, a manufacturer of cable assembly products for the electronics interconnect industry. Between 2006 and 2011, he served as a managing director and national finance practice lead at BBK, Ltd., a turn-around advisory firm. From 2002 to 2005, he served as Group Managing Director of Corporate Restructuring at Huron Consulting Group, LLC. From 2000 to 2002, he was a Managing Director at Berenson Minella & Co., a boutique investment-banking firm. Between 1986 and 2000 he served as a Senior Director at BNP Paribas, where he established and led Paribas Properties, Inc., a real estate investment arm of the bank. In addition, he was a Senior Officer in the bank’s North American asset workout group. Mr. Wexler began his career in 1981 in commercial lease brokerage, asset management, and investment sales at Jones Lang Wootton. He earned a B.A. in Political Science from Johns Hopkins University.
About Brooklyn ImmunoTherapeutics
Brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases. Brooklyn has multiple next-generation cells and gene-editing therapies in preclinical development for various indications including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases.
For more information: https://www.brooklynitx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.